State Street Corp Icosavax, Inc. Transaction History

State Street Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$5.95 - $15.79 $499,597 - $1.33 Million	83,966 Added 15.72%	617,999 $9.74 Million
Q3 2023 Nov 14, 2023	BUY	$7.22 - $10.05 $222,635 - $309,901	30,836 Added 6.13%	534,033 $4.14 Million
Q2 2023 Aug 14, 2023	BUY	$4.89 - $10.57 $206,328 - $445,990	42,194 Added 9.15%	503,197 $5 Million
Q1 2023 May 15, 2023	BUY	$5.62 - $11.51 $9,655 - $19,774	1,718 Added 0.37%	461,003 $2.67 Million
Q4 2022 Feb 14, 2023	BUY	$2.32 - $10.97 $21,571 - $101,999	9,298 Added 2.07%	459,285 $3.65 Million
Q3 2022 Nov 15, 2022	BUY	$3.09 - $9.21 $255,342 - $761,068	82,635 Added 22.49%	449,987 $1.42 Million
Q2 2022 Aug 15, 2022	BUY	$5.7 - $10.33 $47,355 - $85,821	8,308 Added 2.31%	367,352 $2.11 Million
Q1 2022 May 16, 2022	BUY	$4.41 - $22.5 $622,581 - $3.18 Million	141,175 Added 64.8%	359,044 $2.53 Million
Q4 2021 Feb 14, 2022	BUY	$21.07 - $34.98 $680,266 - $1.13 Million	32,286 Added 17.4%	217,869 $4.99 Million
Q3 2021 Nov 15, 2021	BUY	$24.85 - $40.25 $4.61 Million - $7.47 Million	185,583 New	185,583 $5.49 Million

1.37M

Ticker ICVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,885,200
Description
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical tri...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.